Validation of an LC-MS method for the detection and quantification of BZP and TFMPP and their hydroxylated metabolites in human plasma and its application to the pharmacokinetic study of TFMPP in humans.
about
An analysis of legal highs: do they contain what it says on the tin?The clinical toxicology of the designer "party pills" benzylpiperazine and trifluoromethylphenylpiperazine.Current awareness of piperazines: pharmacology and toxicology.Update on 1-benzylpiperazine (BZP) party pills.Recent developments in urinalysis of metabolites of new psychoactive substances using LC-MS.Hepatotoxicity of piperazine designer drugs: up-regulation of key enzymes of cholesterol and lipid biosynthesis.Analysis of U-47700, a Novel Synthetic Opioid, in Human Urine by LC-MS-MS and LC-QToF.In vitro hepatotoxicity of 'Legal X': the combination of 1-benzylpiperazine (BZP) and 1-(m-trifluoromethylphenyl)piperazine (TFMPP) triggers oxidative stress, mitochondrial impairment and apoptosis.Acute effects of the designer drugs benzylpiperazine (BZP) and trifluoromethylphenylpiperazine (TFMPP) using functional magnetic resonance imaging (fMRI) and the Stroop task--a pilot study.Screening of methylenedioxyamphetamine- and piperazine-derived designer drugs in urine by LC-MS/MS using neutral loss and precursor ion scan.Screening of stimulants including designer drugs in urine using a liquid chromatography tandem mass spectrometry system.Determining the subjective and physiological effects of BZP combined with TFMPP in human males.Differential responses to anticipation of reward after an acute dose of the designer drugs benzylpiperazine (BZP) and trifluoromethylphenylpiperazine (TFMPP) alone and in combination using functional magnetic resonance imaging (fMRI).Detection and quantification of 56 new psychoactive substances in whole blood and urine by LC-MS/MS.
P2860
Q33905588-990E9D18-1051-4D41-8FA8-0D0820E8BAEAQ34178580-F23D8547-661E-4D8C-8C86-199970D03F26Q37899848-8FEEE1F5-C5A3-4ABF-B2AB-F610F3B75D6AQ38107787-549FF530-AD60-427B-B215-E7EDD906F827Q38260819-1C121B7E-A176-4D90-9BDA-477BB603A899Q38294121-25F50423-45BD-4BEE-8729-B99DD439E9CAQ38776390-416AF1CD-1FFD-4AAC-B164-FB44B843E526Q39643944-5570ABDC-13A2-4B4E-B3E3-ACC101A3DC0FQ41040391-DA59C2A7-9B59-485C-B64E-ADB81E8A0758Q44758844-A9525E28-FF8E-4715-A24C-BE4CBB7058D6Q48099182-838F3C96-1DA2-4144-B736-5F5B4248B4DEQ50658638-10790F14-D9DB-4AD8-A512-9708DBA81F87Q50744777-9D8E080F-2B5C-469D-B988-7E19898A817FQ53479625-77318232-226E-49BE-AC71-E72346E3D7BE
P2860
Validation of an LC-MS method for the detection and quantification of BZP and TFMPP and their hydroxylated metabolites in human plasma and its application to the pharmacokinetic study of TFMPP in humans.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Validation of an LC-MS method ...... etic study of TFMPP in humans.
@en
Validation of an LC-MS method ...... etic study of TFMPP in humans.
@nl
type
label
Validation of an LC-MS method ...... etic study of TFMPP in humans.
@en
Validation of an LC-MS method ...... etic study of TFMPP in humans.
@nl
prefLabel
Validation of an LC-MS method ...... etic study of TFMPP in humans.
@en
Validation of an LC-MS method ...... etic study of TFMPP in humans.
@nl
P1476
Validation of an LC-MS method ...... etic study of TFMPP in humans.
@en
P2093
Ushtana Antia
P304
P356
10.1111/J.1556-4029.2010.01457.X
P577
2010-06-08T00:00:00Z